The graft-versus-leukemia effect of post-transplant donor leukocyte infusion

Leukemia and Lymphoma

Volumn 23, Issue 1-2, 1996, Pages 1-9

  Johnson, Bryon D ^a   Hanke, Carrie A ^a   Truitt, Robert L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Donor leukocyte infusions; Graft versus leukemia; Posttransplant

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; GRAFT VERSUS HOST REACTION; LEUKEMIA; LEUKOCYTE TRANSFUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029803984     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609054795     Document Type: Review

References (65)

1. Bortin, M. M., Horowitz, M. M. and Rimm, A. A. (1992) Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transpl., 10, 113.
2. Burakoff, S. J., Deeg, H. J., Ferrara, J. and Atkinson, K. (eds.) (1990) Graft-vs-Host Disease: immunology, Pathophysiology, and Treatment, Marcel Dekker, Inc., New York, NY.
3. Korngold, R. (1993) Biology of graft-vs-host disease. Am. J. Ped. Hem. Onc., 15, 18.
4. Vallera, D. A., Soderling, C. C. B., Carlson, G. J. and Kersey, J. H. (1982) Bone marrow transplantation across major histocompatability barriers in mice. II. T cell requirements for engraftment in total lymphoid irradiation-conditioned recipients. Transpl., 33, 243.
5. Blazar, B. R., Filipovich, A. H., Kersey, J. H. et al (1987) T-cell depletion of donor marrow grafts: Effects on graft-versus-host disease and engraftment. IN: Progress in Bone Marrow Transplantation, (RP Gale and R Champlin (eds)), Alan R. Liss, New York, p 381.
6. Truitt, R. L., Shih, C. C.-Y. and LeFever, A. V. (1986) Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma. Transpl., 41, 301.
7. Martin, P. J., Hansen, J. A., Torok-Storb, B. et al. (1988) Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transpl., 3, 445.
8. Martin, P. J., Hansen, J. A., Torok-Storb, B. et al. (1988) Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transpl., 3, 437.
9. Horowitz, M. M., Gale, R. P., Sondel, P. M., Goldman, J. M. et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555.
10. Marmont, A. M., Horowitz, M. M., Gale, R. P., Sobocinski, K. et al. (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood, 78, 2120.
11. Weiden, P. L. and Horowitz, M. M. (1990) Graft-vs-leukemia effects in clinical bone marrow transplantation. IN: Graft-vs-Host Disease, (S. J. Burakoff, H. J. Deeg, J. Ferrara and K. Atkinson (eds)), Marcel Dekker, New York, p 691.
12. Vos, O. and Weyzen, W. W. H. (1962) "Killing effect" of injected lymph node cells in homologous radiation chimeras. Transpl. Bull., 30, 501.
13. Weiden, P. L., Storb, R , Tsoi, M , Graham, T. C. et al. (1976) Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance J. Immunol , 116, 1212.
14. Slavin, S., Fuks, Z., Kaplan, H. S. and Strober, S. (1978) Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation. J. Exp. Med., 147, 963.
15. Kolb, H. J , Mittermuller, J., Clemm, C., Holler, E. et al. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462.
16. Giralt, S. A. and Champlin, R. E. (1994) Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood, 84, 3603.
17. Drobyski, W. R , Roth, M S., Thibodeau, S. N. and Gottschall, J. L. (1992) Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transpl., 10, 301.
18. Cullis, J. O., Jiang, Y. Z , Schwarer, A. P., Hughes, T. P. et al. (1992) Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood, 79, 1379.
19. Frassoni, F., Fagioli, F., Sessarego, M., Gualandi, F. et al. (1992) The effect of donor leukocyte infusion in patients with leukemia following bone marrow transplantation. Exp. Hematol., (Abstract). 20, 712.
20. Drobyski, W. D., Keever, C. A. and Roth, M. S (1993) Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed CML after allogeneic BMT: Efficacy and toxicity of a defined T-cell dose. Blood, 82, 2310.
21. Szer, J., Grigg, A. P. Phillips, G. L. and Sheridan, W. P. (1993) Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transpl., 11, 109
22. Bar, B. M. A. M., Schattenberg, A., Mensink, E. J. B. M., Kessel, A. G V. et al. (1993) Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J. Clin. Oncol., 11, 513
23. Hertenstein, B., Wiesneth, M., Novotny, J., Bunjes, D. et al. (1993) Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transpl., 56, 1114.
24. Helg, C., Roux, E., Beris, P., Cabrol, C. et al. (1993) Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transpl., 12, 125.
25. Leber, B., Walker, I. R., Rodriguez, A., McBride, J. A. et al. (1993) Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: Recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transpl., 12, 405.
26. Porter, D. L., Roth, M. S., McGarigle, C., Ferrara, J. L. M. and Antin, J. H. (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med., 330, 100.
27. van Rhee, F., Cullis, J. O., Spencer, A., Cross, N. C. P. et al. (1994) Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood, 83, 3377.
28. Ferster, A., Bujan, W., Mouraux, T., Devalck, C. et al. (1994) Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transpl., 14, 331.
29. Mehta, J., Powles, R., Singhal, S., Taint, D. et al (1995) Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transpl., 16, 133.
30. Bernasconi, P., Alessandrino, E. P., Caldera, D., Bonfichi, M. et al. (1995) Intensive chemotherapy followed by donor PBSC in ANLL relapsed after allogeneic BMT Bone Marrow Transpl., 15, 643.
31. Mackinnon, S., Papadopoulos, E. B., Carabasi, M. H., Reich, L. et al. (1995) Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: Is T cell dose important in determining biological response? Bone Marrow Transpl., 15, 591.
32. Mackinnon, S., Papadopoulos, E. B., Carabasi, M. H., Reich, L. et al. (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86, 1261.
33. Kolb, H. J., Schattenberg, A., Goldman, J. M., Hertenstein, B. et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041.
34. Jiang, Y. Z., Cullis, J. O., Kanfer, E. J., Goldman, J. M. et al. (1993) T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transpl , 11, 133.
35. Bunjes, D., Theobald, M., Hertenstien, B., Wiesneth, M. et al. (1995) Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells. Bone Marrow Transpl., 15, 713.
36. Papadopoulos, E. B., Ladanyl, M., Emanuel, D., Castro-Malaspina, H. et al. (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl. J. Med., 330, 1185.
37. Hromas, R., Cornetta, K. and Srour, E. (1994) Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation New Engl. J. Med., 330, 1689.
38. Johnson, B. D., Drobyski, W. R. and Truitt, R. L. (1993) Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transpl., 11, 329.
39. Johnson, B. D. and Truitt, R. L. (1995) Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood, 85, 3302.
40. Ferrara, J. L. (1992) Advances in GVHD: Novel lymphocyte subsets and cytokine dysregulation. Bone Marrow Transpl., 10 (S1), 10.
41. Antin, J. and Ferrara, J. (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood, 80, 2964.
42. Ferrara, J., Abhyankar, S. and Gilliland, D. (1993) Cytokine storm of graft-versus-host disease: A critical effector role for interleukin-1. Transpl. Proc., 25, 1216.
43. Truitt, R. L. and Atasoylu, A. A. (1991) Impact of pretransplant conditioning and donor T cells on chimerism, graft-vs-host disease, graft-vs-leukemia reactivity, and tolerance after bone marrow transplantation. Blood, 77, 2515.
44. + T cells to graft-vs-host disease and graft-vs-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transpl., 8, 51.
45. Antin, J. H. (1993) Graft-versus-leukemia: No longer an epiphenomenon. Blood, 82, 2273.
46. Weiss, L., Reich, S. and Slavin, S. (1992) Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest., 10, 19.
47. Sykes, M., Chester, C. H. and Sachs, D. H. (1988) Protection from graft-versus-host disease in fully allogeneic chimeras by prior administration of T cell-depleted syngeneic bone marrow. Transpl., 46, 327.
48. Xun, C. Q., Thompson, J. S., Jennings, C. D., Brown, S. A. et al. (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood, 83, 2360.
49. Frankel, W. N., Rudy, C., Coffin, J. M. and Huber, B. T. (1991) Linkage of Mls genes to endogenous mammary tumour viruses of inbred mice. Nature, 349, 526.
50. a-encoded antigens. Nature, 332, 40.
51. Alters, S.E., Shizuru, J A., Ackerman, J., Grossman, D. et al. (1991) Anti-CD4 mediates clonal anergy during transplantation tolerance induction. J. Exp. Med., 173, 491.
52. DeSilva, D. R., Urdahl, K. B. and Jenkins, M. K. (1991) Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J. Immunol., 147, 3261.
53. Pechhold, K., Pohl, T and Kabelitz, D. (1994) Rapid quantification of lymphocyte subsets in heterogeneous cell populations by flow cytometry. Cytometry, 16, 152.
54. Kabelitz, D., Oberg, H.-H., Pohl, T. and Pechhold, K. (1994) Antigen-induced death of mature lymphocytes: Analysis by flow cytometry Immunol. Rev., 142, 157,
55. Oseroff, A., Okada, S. and Strober, S. (1984) Natural Suppressor (NS) Cells Found in the Spleen of Neonatal Mice and Adult Mice Given Total Lymphoid Irradiation (TLI) Express the Null Surface Phenotype. J. Immunol., 132, 101.
56. Maier, T , Holdä, J. H. and Claman, H. N. (1985) Graft-Vs-Host Reactions (GVHR) Across Minor Murine Histocompatability Barriers. II. Development of Natural Suppressor Cell Activity. J. Immunol., 135, 1644.
57. Sadelain, M. W. J., Green, D. R. and Wegmann, T. G. (1990) Host Natural Suppressor Activity Regulates Hemopoietic Engraftment Kinetics in Antibody-Conditioned Recipient Mice. J. Immunol., 144, 1729.
58. Saffran, D. C. and Singhal, S. K. (1990) Further characterization of murine bone marrow-derived natural suppressor cells. Potential relationships between NS and NK/LAK activities. Cell. Immunol., 128, 301.
59. Sykes, M., Sharabi, Y. and Sachs, D. H. (1990) Natural Suppressor Cells in Spleens of Irradiated. Bone Marrow-Reconstituted Mice and Normal Bone Marrow: Lack of SCA-1 Expression and Enrichment by Depletion of MAC1-Positive Cells. Cell. Immunol , 127, 260.
60. Angulo, I , Rodriguez, R., Garcia, B., Medina, M. et al. (1995) Involvement of nitric oxide in bone marrow-derived natural suppressor activity. J. Immunol., 155, 15.
61. Johnson, B. D. and Truitt, R. L. (1992) Selective depletion of donor NK cells in vivo decreases graft-vs-host disease without the loss of graft-vs-leukemia reactivity after MHC-matched bone marrow transplantation. Transpl., 54, 104.
62. Johnson, B. D., McCabe, C., Hanke, C. A. and Truitt, R. L. (1995) Use of anti-CD3ε F(ab′)2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J. Immunol., 154, 5542.
63. Korngold, R., Leighton, C. and Manser, T. (1994) Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transpl., 58, 278.
64. + cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood, 83, 2560.
65. Bonini, C., Verzeletti, S., Servida, P., Rossini, S. et al. (1994) Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo-BMT. Blood, 84 (S1), 110a.